Advances in immunosuppression for renal transplantation

The development of immunosuppressants with minimal adverse and nephrotoxic effects is important to improve outcomes, such as acute and chronic antibody-mediated rejection, after organ transplantation. In addition, the application of expanded criteria for donors and transplantation in immunized patients necessitates the development of new therapies. Drug development over the past 10 years has generally been disappointing, but several new promising compounds have been or are being developed to prevent acute and chronic transplant rejection. In this Review, we report on several compounds that have been developed to remove allogenic T cells and/or to inhibit T-cell activation. We also discuss compounds that interfere with antibody-mediated rejection.

[1]  Y. Volkov,et al.  Crucial importance of PKC-β(I) in LFA-1–mediated locomotion of activated T cells , 2001, Nature Immunology.

[2]  E. Hsi,et al.  Rapid resolution of GVHD after orthotopic liver transplantation in a patient treated with alefacept. , 2009, Blood.

[3]  Andrew H. Liu,et al.  MUTATIONS OF Jak-3 GENE IN PATIENTS WITH AUTOSOMAL SEVERE COMBINED IMMUNE DEFICIENCY (SCID) , 1996, Pediatrics.

[4]  V. Krishnamurthi.  A Phase III Study of Belatacept-based Immunosuppression Regimens versus Cyclosporine in Renal Transplant Recipients (BENEFIT Study) , 2010 .

[5]  R. Kirken,et al.  Concomitant Inhibition of Janus Kinase 3 and Calcineurin-Dependent Signaling Pathways Synergistically Prolongs the Survival of Rat Heart Allografts1 , 2001, The Journal of Immunology.

[6]  M. Haas,et al.  Antibody-mediated rejection in renal allografts: lessons from pathology. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[7]  Z Chen,et al.  Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  C. Mews.  New Discoveries and Insights (1999–2007) , 2008 .

[9]  Peter Lipsky,et al.  Cytokines and their role in lymphoid development, differentiation and homeostasis , 2002, Current opinion in allergy and clinical immunology.

[10]  G. Cohen,et al.  Caspase-independent cell death induced by anti-CD2 or staurosporine in activated human peripheral T lymphocytes. , 1998, Journal of immunology.

[11]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[12]  R. Brodsky,et al.  Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria , 2007, Nature Biotechnology.

[13]  Y Nishizuka,et al.  Studies on a cyclic nucleotide-independent protein kinase and its proenzyme in mammalian tissues. I. Purification and characterization of an active enzyme from bovine cerebellum. , 1977, The Journal of biological chemistry.

[14]  J. Tuttle-Newhall,et al.  Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection1 , 2003, Transplantation.

[15]  E. Schaeffer,et al.  PKC-θ is required for TCR-induced NF-κB activation in mature but not immature T lymphocytes , 2000, Nature.

[16]  Francis L. Delmonico,et al.  ACUTE HUMORAL REJECTION IN RENAL ALLOGRAFT RECIPIENTS: I. INCIDENCE, SEROLOGY AND CLINICAL CHARACTERISTICS1 , 2001, Transplantation.

[17]  D. Segev,et al.  The Use of Antibody to Complement Protein C5 for Salvage Treatment of Severe Antibody‐Mediated Rejection , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  A. Kirk,et al.  ALEFACEPT PROMOTES COSTIMULATION BLOCKADE BASED ALLOGRAFT SURVIVAL IN PRIMATES , 2009, Nature Medicine.

[19]  T. Larson,et al.  Overcoming a Positive Crossmatch in Living‐Donor Kidney Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  P. Doherty,et al.  Defective Lymphoid Development in Mice Lacking Jak3 , 1995, Science.

[21]  J. Campistol,et al.  A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study) , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[22]  B. Reitz,et al.  Immunosuppression by the JAK3 Inhibitor CP-690,550 Delays Rejection and Significantly Prolongs Kidney Allograft Survival in Nonhuman Primates , 2005, Transplantation.

[23]  J. Kovarik,et al.  The effect on sotrastaurin pharmacokinetics of strong CYP3A inhibition by ketoconazole. , 2009, British journal of clinical pharmacology.

[24]  C. Monks,et al.  Selective modulation of protein kinase C-Θ during T-cell activation , 1997, Nature.

[25]  G. Baier.  The PKC gene module: molecular biosystematics to resolve its T cell functions , 2003, Immunological reviews.

[26]  M. Goldsmith,et al.  JAK/STAT signaling by cytokine receptors. , 1998, Current opinion in immunology.

[27]  R. Brodsky.  How I treat paroxysmal nocturnal hemoglobinuria. , 2009, Blood.

[28]  H. Nakauchi,et al.  Developmental defects of lymphoid cells in Jak3 kinase-deficient mice. , 1995, Immunity.

[29]  M. Sayegh,et al.  CD28-B7 T cell costimulatory blockade by CTLA4Ig in the rat renal allograft model: inhibition of cell-mediated and humoral immune responses in vivo. , 1996, Transplantation.

[30]  H. Bazin,et al.  A Role for CD2 Antibodies (BTI-322 and its Humanized Form) in the in vivo Elimination of Human T Lymphocytes Infiltrating an Allogeneic Human Skin Graft in SCID Mice: An Fc&ggr; Receptor-Related Mechanism Involving Co-Injected Human NK Cells , 2004, Transplantation.

[31]  E. Kamil,et al.  Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients1 , 2003, Transplantation.

[32]  F. Rieux-Laucat,et al.  CD2-induced apoptosis in activated human peripheral T cells: a Fas-independent pathway that requires early protein tyrosine phosphorylation. , 1996, Journal of immunology.

[33]  D. Cantrell,et al.  Protein kinase C and beyond , 2004, Nature Immunology.

[34]  P. Terasaki.  Humoral Theory of Transplantation , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[35]  B. Nelson,et al.  Biology of the interleukin-2 receptor. , 1998, Advances in immunology.

[36]  A. Leonardi,et al.  Mice Deficient in Nuclear Factor (NF)-κB/p52 Present with Defects in Humoral Responses, Germinal Center Reactions, and Splenic Microarchitecture , 1998, The Journal of experimental medicine.

[37]  A. Baldwin,et al.  THE NF-κB AND IκB PROTEINS: New Discoveries and Insights , 1996 .

[38]  M. Karin,et al.  Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. , 1997, The New England journal of medicine.

[39]  P. Linsley,et al.  Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. , 1992, Science.

[40]  Gerhard Zenke,et al.  The Potent Protein Kinase C-Selective Inhibitor AEB071 (Sotrastaurin) Represents a New Class of Immunosuppressive Agents Affecting Early T-Cell Activation , 2009, Journal of Pharmacology and Experimental Therapeutics.

[41]  P. Zipfel,et al.  Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[42]  F. Alt,et al.  Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. , 1995, Immunity.

[43]  M. Stegall,et al.  Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody Production , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[44]  E. Schaeffer,et al.  PKC-theta is required for TCR-induced NF-kappaB activation in mature but not immature T lymphocytes. , 2000, Nature.

[45]  J. Platt,et al.  Acute Vascular Rejection and Accommodation: Divergent Outcomes of the Humoral Response to Organ Transplantation , 2004, Transplantation.

[46]  D. Cosman,et al.  Utilization of the beta and gamma chains of the IL‐2 receptor by the novel cytokine IL‐15. , 1994, The EMBO journal.

[47]  W. Leonard,et al.  Jaks and STATs: biological implications. , 1998, Annual review of immunology.

[48]  G. Baier,et al.  Protein Kinase C (cid:2) Affects Ca 2 (cid:3) Mobilization and NFAT Cell Activation in Primary Mouse T Cells , 2022 .

[49]  A. Alcover,et al.  The tyrosine kinase activity of p56lck is increased in human T cells activated via CD2 , 1991, European journal of immunology.

[50]  B. Reitz,et al.  Effects of JAK3 Inhibition with CP-690,550 on Immune Cell Populations and Their Functions in Nonhuman Primate Recipients of Kidney Allografts , 2005, Transplantation.

[51]  M. Sayegh,et al.  Immunosuppressive strategies in transplantation , 1999, The Lancet.

[52]  D. Taub,et al.  Tyrphostin AG‐490 inhibits cytokine‐mediated JAK3/STAT5a/b signal transduction and cellular proliferation of antigen‐activated human T cells , 1999, Journal of leukocyte biology.

[53]  C. Snapper,et al.  Nuclear Factor (NF)-κB2 (p100/p52) Is Required for Normal Splenic Microarchitecture and B Cell–mediated Immune Responses , 1998, The Journal of experimental medicine.

[54]  E. Masuda,et al.  A Novel JAK3 Inhibitor, R348, Attenuates Chronic Airway Allograft Rejection , 2009, Transplantation.

[55]  B. Reitz,et al.  Combined Use of the JAK3 Inhibitor CP-690,550 with Mycophenolate Mofetil to Prevent Kidney Allograft Rejection in Nonhuman Primates , 2005, Transplantation.

[56]  B. Charpentier,et al.  Targeting additional costimulatory pathways: a subtle role for CD2. , 2001, Transplantation proceedings.

[57]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[58]  D. Métivier,et al.  Mitogenic CD2 monoclonal antibody pairs predispose peripheral T cells to undergo apoptosis on interaction with a third CD2 monoclonal antibody. , 1994, Journal of immunology.

[59]  P. Linsley,et al.  Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors. , 1994, Immunity.

[60]  M. Lebwohl,et al.  An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. , 2003, Archives of dermatology.

[61]  J. O’Shea,et al.  A new modality for immunosuppression: targeting the JAK/STAT pathway , 2004, Nature Reviews Drug Discovery.

[62]  P. Linsley,et al.  T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[63]  W. Duguid,et al.  Role of proteasomes in T cell activation and proliferation. , 1998, Journal of immunology.

[64]  Brown,et al.  Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. , 1994, Blood.

[65]  Seng-Lai Tan,et al.  Emerging and diverse roles of protein kinase C in immune cell signalling. , 2003, The Biochemical journal.

[66]  R. Ahmed,et al.  Humoral immunity due to long-lived plasma cells. , 1998, Immunity.

[67]  M. Boothby,et al.  References Subscriptions Permissions Email Alerts Inhibition of NF-κB-Dependent T Cell Activation Abrogates Acute Allograft Rejection , 2013 .

[68]  H. Stockinger,et al.  SUPPRESSION OF PRIMARY T-CELL RESPONSES AND INDUCTION OF ALLOANTIGEN-SPECIFIC HYPORESPONSIVENESS IN VITRO BY THE JANUS KINASE INHIBITOR TYRPHOSTIN AG4901 , 2000, Transplantation.

[69]  W. Gulliver,et al.  A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. , 2002, Journal of the American Academy of Dermatology.

[70]  M J May,et al.  NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.

[71]  G. Baier,et al.  Defective IgG2a/2b class switching in PKC alpha-/- mice. , 2006, Journal of immunology.

[72]  C. Marboe,et al.  Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. , 1996, Transplantation.

[73]  R. Abraham,et al.  Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. , 1998, Current opinion in immunology.

[74]  F. Alt,et al.  Delayed lymphoid repopulation with defects in IL-4-driven responses produced by inactivation of NF-ATc. , 1998, Immunity.

[75]  R. Colvin.  Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. , 2007, Journal of the American Society of Nephrology : JASN.

[76]  I. Horak,et al.  Development and function of T cells in mice rendered interleukin-2 deficient by gene targeting , 1991, Nature.

[77]  T. Kawai,et al.  Long-term results of ABO-incompatible living kidney transplantation: a single-center experience. , 1998 .

[78]  L. Berg,et al.  The role of Jak3 in lymphoid development, activation, and signaling. , 1997, Current opinion in immunology.

[79]  P. Changelian,et al.  The JAK3 inhibitor CP‐690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing , 2004, Journal of leukocyte biology.

[80]  S. Bromley,et al.  The immunological synapse. , 2001, Annual review of immunology.

[81]  R. Alloway,et al.  Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute Rejection , 2008, Transplantation.

[82]  Markus Exner,et al.  Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: a contribution of humoral immunity to chronic allograft rejection. , 2002, Journal of the American Society of Nephrology : JASN.

[83]  D. Harlan,et al.  INDUCTION THERAPY WITH MONOCLONAL ANTIBODIES SPECIFIC FOR CD80 AND CD86 DELAYS THE ONSET OF ACUTE RENAL ALLOGRAFT REJECTION IN NON-HUMAN PRIMATES1 , 2001, Transplantation.

[84]  Jeffrey A. Bluestone,et al.  When ligand becomes receptor—tolerance via B7 signaling on DCs , 2002, Nature Immunology.

[85]  R. Montgomery,et al.  PLASMAPHERESIS AND INTRAVENOUS IMMUNE GLOBULIN PROVIDES EFFECTIVE RESCUE THERAPY FOR REFRACTORY HUMORAL REJECTION AND ALLOWS KIDNEYS TO BE SUCCESSFULLY TRANSPLANTED INTO CROSS-MATCH-POSITIVE RECIPIENTS , 2000, Transplantation.

[86]  C. June,et al.  Increases in tyrosine phosphorylation are detectable before phospholipase C activation after T cell receptor stimulation. , 1990, Journal of immunology.

[87]  S. Bixler,et al.  Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses , 1993, The Journal of experimental medicine.

[88]  A. Kirk,et al.  What's Next in the Pipeline , 2008, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[89]  Y. Volkov,et al.  Crucial importance of PKC-beta(I) in LFA-1-mediated locomotion of activated T cells. , 2001, Nature immunology.

[90]  G. Baier,et al.  Defective IgG2a/2b Class Switching in PKCα−/− Mice1 , 2006, The Journal of Immunology.

[91]  G. Freeman,et al.  The B7 family revisited. , 2005, Annual review of immunology.

[92]  A. Levitzki,et al.  Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. , 1991, Journal of medicinal chemistry.

[93]  A. Levitzki,et al.  Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor , 1996, Nature.

[94]  G. Berry,et al.  Janus kinase 3 inhibition with CP‐690,550 prevents allograft vasculopathy , 2006, Transplant international : official journal of the European Society for Organ Transplantation.

[95]  A. Sharpe,et al.  Defects in B Lymphocyte Maturation and T Lymphocyte Activation in Mice Lacking Jak3 , 1995, Science.

[96]  C. Monks,et al.  Selective modulation of protein kinase C-theta during T-cell activation. , 1997, Nature.

[97]  S. Beaudreuil,et al.  Absence of CD4CD25 regulatory T cell expansion in renal transplanted patients treated in vivo with Belatacept mediated CD28-CD80/86 blockade. , 2007, Transplant immunology.

[98]  B. Jaffee,et al.  Mice deficient in PKC theta demonstrate impaired in vivo T cell activation and protection from T cell-mediated inflammatory diseases , 2006, Autoimmunity.

[99]  A. Dam.  Diagnosis and pathogenesis of CNS lupus , 2004, Rheumatology International.

[100]  M. Kopf,et al.  T-cell fate and function: PKC-theta and beyond. , 2008, Trends in immunology.

[101]  A. Baldwin,et al.  The NF-kappa B and I kappa B proteins: new discoveries and insights. , 1996, Annual review of immunology.

[102]  M. Stegall,et al.  Accommodation in ABO‐Incompatible Kidney Allografts, a Novel Mechanism of Self‐Protection Against Antibody‐Mediated Injury , 2003, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[103]  F. Tedla.  Costimulation Blockade With Belatacept in Renal Transplantation , 2006 .

[104]  W. Leonard,et al.  Mutation of Jak3 in a Patient with SCID: Essential Role of Jak3 in Lymphoid Development , 1995, Science.

[105]  U. Grohmann,et al.  CTLA-4–Ig regulates tryptophan catabolism in vivo , 2002, Nature Immunology.

[106]  T. Pruett.  Abrogation of Anti-HLA Antibodies via Proteasome Inhibition , 2010 .

[107]  D. Harlan,et al.  CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[108]  A. Sheil,et al.  Cancer risk associated with ATG/OKT3 in renal transplantation. , 1999, Transplantation proceedings.

[109]  D. Kioussis,et al.  Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. , 1994, Journal of immunology.

[110]  M. Zand,et al.  TREATMENT OF C4D-POSITIVE ACUTE HUMORAL REJECTION WITH PLASMAPHERESIS AND RABBIT POLYCLONAL ANTITHYMOCYTE GLOBULIN , 2004, Transplantation.

[111]  P. Tsirigotis,et al.  Alefacept treatment for refractory chronic extensive GVHD , 2009, Bone Marrow Transplantation.

[112]  Y. Volkov,et al.  Cutting Edge: Protein Kinase Cβ Expression Is Critical for Export of IL-2 from T Cells1 , 2001, The Journal of Immunology.

[113]  P. Nickerson,et al.  IL-2 knockout recipient mice reject islet cell allografts. , 1995, Journal of immunology.

[114]  T. Maniatis,et al.  NF-kappa B: a lesson in family values. , 1995, Cell.

[115]  B. Gelman,et al.  A novel mechanism of CD4 lymphocyte depletion involves effects of HIV on resting lymphocytes: induction of lymph node homing and apoptosis upon secondary signaling through homing receptors. , 1999, Journal of immunology.

[116]  P. Linsley,et al.  Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways , 1996, Nature.

[117]  T. Maniatis,et al.  NF-κB: A lesson in family values , 1995, Cell.

[118]  P. Alzari,et al.  Interleukin 2 and its receptors: recent advances and new immunological functions. , 1996, Immunology today.

[119]  P. Linsley,et al.  Transplantation tolerance induced by CTLA4-Ig. , 1994, Transplantation.

[120]  B. Charpentier,et al.  Effects of anti-CD2 monoclonal antibody: CD2- and CD95-mediated apoptosis of human peripheral T cells. , 1999, Transplantation proceedings.

[121]  M. McHeyzer-Williams,et al.  B cell memory and the long-lived plasma cell. , 1999, Current opinion in immunology.